- Home
- AQB vs VTAK Comparison
AQB vs VTAK Comparison
Compare AQB & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- VTAK
- Stock Information
- Founded
- AQB 1991
- VTAK 2002
- Country
- AQB United States
- VTAK United States
- Employees
- AQB N/A
- VTAK N/A
- Industry
- AQB
- VTAK Medical/Dental Instruments
- Sector
- AQB
- VTAK Health Care
- Exchange
- AQB Nasdaq
- VTAK Nasdaq
- Market Cap
- AQB 2.9M
- VTAK 3.1M
- IPO Year
- AQB N/A
- VTAK 2018
- Fundamental
- Price
- AQB $0.82
- VTAK $0.30
- Analyst Decision
- AQB
- VTAK
- Analyst Count
- AQB 0
- VTAK 0
- Target Price
- AQB N/A
- VTAK N/A
- AVG Volume (30 Days)
- AQB 139.7K
- VTAK 41.4M
- Earning Date
- AQB 08-05-2025
- VTAK 08-13-2025
- Dividend Yield
- AQB N/A
- VTAK N/A
- EPS Growth
- AQB N/A
- VTAK N/A
- EPS
- AQB N/A
- VTAK N/A
- Revenue
- AQB N/A
- VTAK $481,000.00
- Revenue This Year
- AQB N/A
- VTAK $822.86
- Revenue Next Year
- AQB N/A
- VTAK $168.42
- P/E Ratio
- AQB N/A
- VTAK N/A
- Revenue Growth
- AQB N/A
- VTAK 9.57
- 52 Week Low
- AQB $0.47
- VTAK $0.16
- 52 Week High
- AQB $1.94
- VTAK $8.40
- Technical
- Relative Strength Index (RSI)
- AQB 49.12
- VTAK 50.43
- Support Level
- AQB $0.72
- VTAK $0.25
- Resistance Level
- AQB $0.85
- VTAK $0.38
- Average True Range (ATR)
- AQB 0.07
- VTAK 0.07
- MACD
- AQB -0.01
- VTAK 0.01
- Stochastic Oscillator
- AQB 36.27
- VTAK 18.46
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.